Alzheimer, Drugs and Systematic Reviews
Digest more
UCF researchers have uncovered evidence that some movement-related symptoms of Alzheimer's disease may originate outside the brain, which could change how the disease is diagnosed and treated in the future.
It’s “a move away from a one-size-fits-all framework for Alzheimer’s disease.”
The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein called amyloid-β was responsible for memory loss in Alzheimer’s disease. On its own, that might not seem notable; bad papers can make it through peer review and are only caught after publication.
Does Alzheimer’s start in the muscles? Research reveals that motor neuron mutations disrupt the neuromuscular junction independent of the brain.
Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.
New findings show that a condition that affects 10% of US adults over 65 is likely increasing their risk of dementia by more than half. The good news, though, is that the condition is mostly treatable.
Diabetes is associated with an increased risk of dementia, and a few drugs for Type 2 diabetes, including metformin and a class of medication called sodium-glucose cotransporter 2 (SGLT2) inhibitors, appear to modestly lower that risk, though some studies don’t show an effect.
Gates is a supporter of Alzheimer’s research, but scammers are using his name and likeness to promote fraudulent “cures” for the disease.